SUPIDIMIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C12H12N2O4S
Molecular Weight	280.3
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O=C1N(C2CCCNC2=O)S(=O)(=O)C3=C1C=CC=C3

InChI

InChIKey=QQWLXNMPPFCVCD-UHFFFAOYSA-N

InChI=1S/C12H12N2O4S/c15-11-9(5-3-7-13-11)14-12(16)8-4-1-2-6-10(8)19(14,17)18/h1-2,4,6,9H,3,5,7H2,(H,13,15)

HIDE SMILES / InChI

Molecular Formula	C12H12N2O4S
Molecular Weight	280.3
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7049709 | https://www.ncbi.nlm.nih.gov/pubmed/2867921 | https://www.ncbi.nlm.nih.gov/pubmed/6664155

Supidimide is a benzisothiazol derivative patented by Chemie Gruenenthal G.m.b.H. as a sedative and hypnotic agent. Supidimide acts as serotonin release inhibitor and decreases of 5-HT release into the synaptic cleft in preclinical studies. In clinical trials, Supidimide substantially relieved sleep disturbances in schizophrenic inpatients. Besides that Supidimide administration associated with a decrease in "somatic concern", items related to agitation, "irritability" and "manifest psychosis", and a slight increase in "retardation".

Originator

Approval Year

PubMed

Title	Date	PubMed
The effect of thalidomide and 2 analogs on collagen induced arthritis.	1998 May	9598899

Patents

Sample Use Guides

In Vivo Use Guide

2 x 200 mg per day.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:28:21 GMT 2023` Edited by `admin` on `Fri Dec 15 15:28:21 GMT 2023`
Record UNII	L2GWR3US1G
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SUPIDIMIDE

Official Name

English

supidimide [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29756